A Comprehensive Review of Immunotherapies in Prostate Cancer

Highlights • Although prostate cancer expresses many tumor associated antigens, its microenvironment is relative immunosuppressive. • Sipuleucel-T is the only approved immunotherapy for prostate cancer and has driven major enthusiasm for testing new agents in this disease. • Various other immune age...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2017-05, Vol.113, p.292-303
Main Authors: Maia, Manuel Caitano, Hansen, Aaron R
Format: Article
Language:English
Subjects:
Cancer Vaccines - therapeutic use
Castration-resistant
Clinical Trials as Topic
CTLA-4 Antigen - antagonists & inhibitors
Hematology, Oncology and Palliative Medicine
Humans
Immune checkpoint inhibitor
Immunotherapy
Immunotherapy - methods
Male
Metastatic
Oncolytic viruses
Prostate cancer
Prostatic Neoplasms - immunology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Tissue Extracts - therapeutic use
Tumor Microenvironment
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753
cites cdi_FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753
container_end_page 303
container_issue
container_start_page 292
container_title Critical reviews in oncology/hematology
container_volume 113
creator Maia, Manuel Caitano
Hansen, Aaron R
description Highlights • Although prostate cancer expresses many tumor associated antigens, its microenvironment is relative immunosuppressive. • Sipuleucel-T is the only approved immunotherapy for prostate cancer and has driven major enthusiasm for testing new agents in this disease. • Various other immune agents have been tested but failed to show clinical benefit in prostate cancer. • Appropriate patient selection and trial design are crucial; and need to be tailored to account for the unique pharmacodynamics and clinical outcomes of immunotherapies. • Here we review the data on completed trials and conclude with future directions, highlighting important aspects that need to be addressed to improve the evaluation of immunotherapies in prostate cancer.
doi_str_mv 10.1016/j.critrevonc.2017.02.026
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891128666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842817300239</els_id><sourcerecordid>1891128666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753</originalsourceid><addsrcrecordid>eNqNkdtq3DAQhkVpyCbbvELxZW680chaHSAU0qWHQKAhSa-FVh6z2tjWRrK35O0js2kKuSoMSAz_P4dvCCmALoCCuNguXPRDxH3o3YJRkAvKcogP5ASU1CXlAj7mP-W0VJypGTlNaUsp5VzIYzJjOSmXoE_I5VWxCt0u4gb75PdY3OHe458iNMV11419GDYY7c5jKnxf3MaQBjtgsbK9w_iJHDW2TXj2-s7J7-_fHlY_y5tfP65XVzel40wP5RpkI7lEXTstFFNacMuWFnmlWc25o8u1bDivFDi5RpCqqUDImmtuhajkspqT80PdXQxPI6bBdD45bFvbYxiTAaUBmBJZPSfqIHV51BSxMbvoOxufDVAzsTNb84-dmdgZynJM1s-vXcZ1h_Wb8S-sLPh6EGDeNVOKJjmPGUTtI7rB1MH_T5cv74q41vfe2fYRnzFtwxj7zNKASdlg7qcbTicEWVHKKl29AO4fmKI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1891128666</pqid></control><display><type>article</type><title>A Comprehensive Review of Immunotherapies in Prostate Cancer</title><source>ScienceDirect Freedom Collection</source><creator>Maia, Manuel Caitano ; Hansen, Aaron R</creator><creatorcontrib>Maia, Manuel Caitano ; Hansen, Aaron R</creatorcontrib><description>Highlights • Although prostate cancer expresses many tumor associated antigens, its microenvironment is relative immunosuppressive. • Sipuleucel-T is the only approved immunotherapy for prostate cancer and has driven major enthusiasm for testing new agents in this disease. • Various other immune agents have been tested but failed to show clinical benefit in prostate cancer. • Appropriate patient selection and trial design are crucial; and need to be tailored to account for the unique pharmacodynamics and clinical outcomes of immunotherapies. • Here we review the data on completed trials and conclude with future directions, highlighting important aspects that need to be addressed to improve the evaluation of immunotherapies in prostate cancer.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2017.02.026</identifier><identifier>PMID: 28427519</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cancer Vaccines - therapeutic use ; Castration-resistant ; Clinical Trials as Topic ; CTLA-4 Antigen - antagonists &amp; inhibitors ; Hematology, Oncology and Palliative Medicine ; Humans ; Immune checkpoint inhibitor ; Immunotherapy ; Immunotherapy - methods ; Male ; Metastatic ; Oncolytic viruses ; Prostate cancer ; Prostatic Neoplasms - immunology ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Tissue Extracts - therapeutic use ; Tumor Microenvironment ; Vaccination ; Vaccines</subject><ispartof>Critical reviews in oncology/hematology, 2017-05, Vol.113, p.292-303</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753</citedby><cites>FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28427519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maia, Manuel Caitano</creatorcontrib><creatorcontrib>Hansen, Aaron R</creatorcontrib><title>A Comprehensive Review of Immunotherapies in Prostate Cancer</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Highlights • Although prostate cancer expresses many tumor associated antigens, its microenvironment is relative immunosuppressive. • Sipuleucel-T is the only approved immunotherapy for prostate cancer and has driven major enthusiasm for testing new agents in this disease. • Various other immune agents have been tested but failed to show clinical benefit in prostate cancer. • Appropriate patient selection and trial design are crucial; and need to be tailored to account for the unique pharmacodynamics and clinical outcomes of immunotherapies. • Here we review the data on completed trials and conclude with future directions, highlighting important aspects that need to be addressed to improve the evaluation of immunotherapies in prostate cancer.</description><subject>Cancer Vaccines - therapeutic use</subject><subject>Castration-resistant</subject><subject>Clinical Trials as Topic</subject><subject>CTLA-4 Antigen - antagonists &amp; inhibitors</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immune checkpoint inhibitor</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Male</subject><subject>Metastatic</subject><subject>Oncolytic viruses</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - immunology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Tissue Extracts - therapeutic use</subject><subject>Tumor Microenvironment</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNkdtq3DAQhkVpyCbbvELxZW680chaHSAU0qWHQKAhSa-FVh6z2tjWRrK35O0js2kKuSoMSAz_P4dvCCmALoCCuNguXPRDxH3o3YJRkAvKcogP5ASU1CXlAj7mP-W0VJypGTlNaUsp5VzIYzJjOSmXoE_I5VWxCt0u4gb75PdY3OHe458iNMV11419GDYY7c5jKnxf3MaQBjtgsbK9w_iJHDW2TXj2-s7J7-_fHlY_y5tfP65XVzel40wP5RpkI7lEXTstFFNacMuWFnmlWc25o8u1bDivFDi5RpCqqUDImmtuhajkspqT80PdXQxPI6bBdD45bFvbYxiTAaUBmBJZPSfqIHV51BSxMbvoOxufDVAzsTNb84-dmdgZynJM1s-vXcZ1h_Wb8S-sLPh6EGDeNVOKJjmPGUTtI7rB1MH_T5cv74q41vfe2fYRnzFtwxj7zNKASdlg7qcbTicEWVHKKl29AO4fmKI</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Maia, Manuel Caitano</creator><creator>Hansen, Aaron R</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>A Comprehensive Review of Immunotherapies in Prostate Cancer</title><author>Maia, Manuel Caitano ; Hansen, Aaron R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cancer Vaccines - therapeutic use</topic><topic>Castration-resistant</topic><topic>Clinical Trials as Topic</topic><topic>CTLA-4 Antigen - antagonists &amp; inhibitors</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immune checkpoint inhibitor</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Male</topic><topic>Metastatic</topic><topic>Oncolytic viruses</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - immunology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Tissue Extracts - therapeutic use</topic><topic>Tumor Microenvironment</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maia, Manuel Caitano</creatorcontrib><creatorcontrib>Hansen, Aaron R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maia, Manuel Caitano</au><au>Hansen, Aaron R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comprehensive Review of Immunotherapies in Prostate Cancer</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>113</volume><spage>292</spage><epage>303</epage><pages>292-303</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Highlights • Although prostate cancer expresses many tumor associated antigens, its microenvironment is relative immunosuppressive. • Sipuleucel-T is the only approved immunotherapy for prostate cancer and has driven major enthusiasm for testing new agents in this disease. • Various other immune agents have been tested but failed to show clinical benefit in prostate cancer. • Appropriate patient selection and trial design are crucial; and need to be tailored to account for the unique pharmacodynamics and clinical outcomes of immunotherapies. • Here we review the data on completed trials and conclude with future directions, highlighting important aspects that need to be addressed to improve the evaluation of immunotherapies in prostate cancer.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28427519</pmid><doi>10.1016/j.critrevonc.2017.02.026</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1040-8428
ispartof Critical reviews in oncology/hematology, 2017-05, Vol.113, p.292-303
issn 1040-8428
1879-0461
language eng
recordid cdi_proquest_miscellaneous_1891128666
source ScienceDirect Freedom Collection
subjects Cancer Vaccines - therapeutic use
Castration-resistant
Clinical Trials as Topic
CTLA-4 Antigen - antagonists & inhibitors
Hematology, Oncology and Palliative Medicine
Humans
Immune checkpoint inhibitor
Immunotherapy
Immunotherapy - methods
Male
Metastatic
Oncolytic viruses
Prostate cancer
Prostatic Neoplasms - immunology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Tissue Extracts - therapeutic use
Tumor Microenvironment
Vaccination
Vaccines
title A Comprehensive Review of Immunotherapies in Prostate Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T23%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comprehensive%20Review%20of%20Immunotherapies%20in%20Prostate%20Cancer&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Maia,%20Manuel%20Caitano&rft.date=2017-05-01&rft.volume=113&rft.spage=292&rft.epage=303&rft.pages=292-303&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2017.02.026&rft_dat=%3Cproquest_cross%3E1891128666%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-b17f747e9dc96828964a25ae4392d44c05b7f44381c7be178f3167d494a663753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1891128666&rft_id=info:pmid/28427519&rfr_iscdi=true